🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

And it’s so nice to be able to prove that in a randomized study .. I hope regulatory folks and other stakeholders realize how hard it is to do #RCTs in #bmtsm

Recap of Day 3 of European Hematology Association 2025: Top Trials Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | Eddie Cliff |. Taha A, MD | Simon Stern | awechalekar | Victor H Jimenez-Zepeda |

Look at these PFS curves in high risk R/R FL .. #CARtcell (one time infusion) is likely curative for this disease too #bmtsm #CellTherapy #lymsm

Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

Aaron Goodman - “Papa Heme” MMF is the key omission in this trial. Would love to try omitting MMF, at least in fully matched donors. CNI still important, even in CAST, but maybe allow for early discontinuation?

Hemant S. Murthy MD Aaron Goodman - “Papa Heme” The data to support the use of MMF for GvHd prevention is scarce, if any. It might even be detrimental with increased risk of relapse. CNI duration has been shortened in CAST. We are working on totally CNI- mTOR-free regimen. Stay tuned.

#ASCO25

THUNDER UP .. lets win this game OKC THUNDER NBA

Good benchmarking data #CARtcell #CellTherapy

⚡️⚡️⚡️ THUNDER UP⚡️⚡️⚡️OKC THUNDER

CONGRESS | #18ICML | PRESENTATION Christopher Fox Chris Fox Uni of Nottingham #WeAreUoN presents results from Cohort 1 of the phase II PRiZM+ study assessing the safety and efficacy of the zanubrutinib monotherapy in patients with R/R PCNSL (N = 20). The ORR at 8 weeks was 50%, with a

Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) remains a known curative therapy in relapsed or refractory B- cell lymphomas , fortunately #CARtcell is curing many now but some patients may still benefit from this procedure #bmtsm #lymsm

If disease is still chemo sensitive at relapse (most are late relapses) then HDC-ASCT is probably just as effective as CD19 #CARtcell , CIBMTR showed similar findings. Future more potent CAR constructs may change this though #lymsm

Maryam is a ⭐️ resident and a future oncologist , any Heme/Onc program will be lucky to have her

CD3/CD20 BITEs combined with ADCs (Pola, Lonca) showing great results in even relapsed aggressive B-cell lymphomas .. are we seeing new synergy with this combo ? #lymsm

⚡️⚡️⚡️

⚡️⚡️ Thunder Up OKC , Game 7 OKC THUNDER ⚡️⚡️

⚡️ THEY DID IT , THUNDER UP .. Congrats Oklahoma City & OKC THUNDER NBA ⚡️

#NewProfilePic 🏆

Huge step forward #CellTherapy